IHL 0.00% 4.1¢ incannex healthcare limited

Ann: IHL-42X positive phase 2 clinical trial results, page-199

  1. 1 Posts.
    lightbulb Created with Sketch. 8
    Your use of the term "the market is always right" is lacking nuance here. If the market was always right there would be no such thing as "oversold" and "overbought"

    I agree that in the long term the market is the best indicator of the correct price but the market can react irrationally in the short term and often does.

    The other problem with that statement is that it implies that the majority of people that sold today were able to make an informed decision of the results without the full clinical information within minutes of the announcement being released.

    Add to this the fact that anticipation of this announcement was well publicised and long awaited as a large price catalyst for IHL so swing traders who have no conviction in the company or the results would have bought in to ride the high. Their intention would have always been to sell on the news, don't underestimate what this can do to the price in one day of trading.

    Let's wait for the information to be digested by smart money as I don't imagine institutions were sitting there refreshing the CommSec app waiting for the results to come in only to make a decision within minutes of the information being released. Let's also wait for some liquidity to build up in the nasdaq where these type of results are better understood by investors.

    I'm not necessarily saying that I know they will react to the results any better but I wouldn't jump to conclusions that the results are terrible before smart money and nasdaq investors have digested it yet.

    All this being said if you are well versed in biotech stocks I'd love to hear your thoughts as to why the market reaction was correct? I ask this genuinely because I'm definitely not an expert and from what I read the results seem very promising but am open to being schooled on it.
 
watchlist Created with Sketch. Add IHL (ASX) to my watchlist

Currently unlisted public company.

arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.